Biotech

All Articles

Ascendis' dwarfism medicine hits in phase 3, threatens BioMarin

.Ascendis Pharma has actually become a prospective risk to BioMarin's Voxzogo, disclosing phase 3 gr...

Despite ph. 3 miss out on, Alkeus observes pathway in advance for eye condition property

.Though Alkeus Pharmaceuticals' dental eye ailment asset stopped working to dramatically reduce geog...

Kairos goes social with $6M IPO to finance trials of cancer cells medicine

.With a trio of biotechs reaching the Nasdaq on Friday, it was effortless to miss out on a smaller-s...

Vaccine as well as Keytruda combo helpful in squamous cell carcinoma

.Immune system checkpoint preventions are actually the superheroes of cancer cells therapy. Medicine...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of considerable leadership hirings, firings a...

Regeneron's Opdualag opponent reveals 57% feedback cost

.Regeneron is back along with lasting follow-up for its own LAG-3 inhibitor as well as PD-1 inhibito...

AstraZeneca messages information on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early consider the efficiency of its in-house antibody-dr...

iTeos- GSK's TIGIT celebrity presents significant enhancement

.After announcing a phase 3 launch based on positive midstage outcomes, iTeos as well as GSK are fin...

More collective FDA may speed up unusual illness R&ampD: file

.The FDA must be actually much more open as well as joint to discharge a rise in commendations of un...

Zenas, MBX, Bicara head to Nasdaq in scorching time for biotech IPOs

.It's an uncommonly active Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicara ...